Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
about
H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependencyStructure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problemPhenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cellsSynergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cellsRhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistanceEffects of estrogen on breast cancer development: Role of estrogen receptor independent mechanismsIndole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop.During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.Role of epigenetic modifications in luminal breast cancer.Breast cancer stem cells and their role in resistance to endocrine therapy.Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.Ethyl 4-(4-methylphenyl)-4-pentenoate from Vetiveria zizanioides Inhibits Dengue NS2B-NS3 Protease and Prevents Viral Assembly: A Computational Molecular Dynamics and Docking Study.Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy.
P2860
Q24322697-D2277B86-0E66-462A-B498-FB0716789EA0Q26829549-D9D1FEBA-488E-431E-AFEA-055853D6BD91Q28396209-15BBC008-C12F-4857-A8BF-543A7FF3847CQ28397373-22D63231-E028-4AEA-844E-EB9FC6A64D9EQ28482597-CCF5A385-F754-4E19-A57D-2CD5ADBBEFBDQ30360376-1F3DD654-8C7F-4AE2-B3E8-2A1F188AB4B6Q33761468-899BA436-57AB-40BD-A13D-7CC9DFF77713Q35029586-4CB8374D-8569-4CFC-A122-00695E209C90Q35932634-96E94333-D7A1-4F50-8F01-5ADC3965B94CQ35963443-257240B4-548C-4AF4-91A9-2D81D1388D6EQ37901429-DF716994-FC9C-4E2C-8EB9-A350980A68B2Q38851061-E0FC5FFA-6149-48ED-BE1F-BC9CE2CF4683Q40100572-667CD766-9F73-4103-8A55-04FA54E71CB0Q42367979-11D4F7EF-E80F-4D35-B289-39EB0415BFB4Q49163340-0D7102B0-3C95-437E-A266-D4977131A0C2
P2860
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
@en
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
@nl
type
label
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
@en
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
@nl
prefLabel
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
@en
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
@nl
P2093
P2860
P1476
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines
@en
P2093
Eric Badia
Joan Oliva
Patrick Balaguer
Vincent Cavaillès
P2860
P304
P356
10.2174/092986707782794023
P577
2007-01-01T00:00:00Z